Fuzydovaya acid | Fucicort cream for external use, 5 g 1 drops 5 pf62 1 drop
Special Price
$20.58
Regular Price
$28.00
In stock
SKU
BID462650
Latin name
Fucitalmic
Fucitalmic
Latin name
Fucitalmic
Release form
Futsitalmik. Eye drops in the form of a viscous suspension of white or almost white.
Packaging
In an aluminum tube 5 g drops. In the package 1 tube with a plastic tip.
cell. Pharmacological action of
Fusidic acid belongs to the group of fusidines, antimicrobial compounds whose mechanism of action is associated with impaired protein synthesis in the bacterial cell. By blocking the elongation of factor G, they prevent its binding to ribosomes and guanosine triphosphate, which interrupts the release of energy necessary for protein synthesis, and leads to the death of a bacterial cell.
Active against the microorganisms most commonly causing eye infections: Staphylococcus aureus.
Streptococcus pneumoniae.
Haemophilus influenzae.
Enterobacteriaciae and Pseudomonas spp. resistant to fusidic acid.
Pharmacokinetics
The dosage form of the drug (viscous eye drops) provides long-term contact with the conjunctiva and a sufficient concentration of fusidic acid in the lacrimal fluid, provided that it is used 2 times / day.
After 1, 3, 6 and 12 hours after a single application of Fucitalmic, the average concentration of fusidic acid in the tear fluid is 15.7 15.2 10.5 and 5.6 μg / ml, respectively. In the intraocular fluid, the concentration of fusidic acid is 0. 3 μg / ml (after single use) and 0.8 μg / ml (after repeated use), is achieved within 1 hour after application and is maintained for at least 12 hours, while fusidic acid is not detected in blood serum.
Indications
Treatment of bacterial infections of the eyes caused by microorganisms susceptible to the drug: Conjunctivitis.
blepharitis.
Keratitis.
Dacryocystitis.
Contraindications
Hypersensitivity to the components of the drug.
Preservative (benzalkonium chloride) is a potential allergen.
Use during pregnancy and lactation
There is no sufficient experience with the use of the drug during pregnancy and lactation (breastfeeding). It is possible to use as prescribed by the attending physician if the expected therapeutic effect exceeds the risk of developing possible side effects.
Composition of
1 g of eye drops contains:
Active ingredients
Fusidic acid micronized (in terms of anhydrous acid) 10 mg, equivalent to fusidic acid hemihydrate 10.17 mg.
Excipients
Benzalkonium chloride, disodium edetate, mannitol, carbomer 974P, sodium hydroxide, purified water.
Dosage and administration
1 drop in the conjunctival sac of the affected eye 2 times / day for 7 days.
In the absence of positive dynamics within 7 days of the use of the drug, therapy should be reviewed using other drugs.
Side effects
From the side of the organ of vision: in rare cases, allergic reactions (in the form of edema of the follicles of the transitional fold of the conjunctiva and urticaria) itching, burning, conjunctival hyperemia, soreness, lacrimation, swelling of the eyelids, aggravation of conjunctivitis.
Futsitalmik therapy should be discontinued in case of signs of hypersensitivity to the drug.
Drug Interaction
There are no drug interaction data.
Overdose
There is no overdose on the drug.
Storage conditions
At a temperature not exceeding 25 РC.
Shelf suitability
3 Year
Deystvuyuschee substances
Fuzydovaya acid
pharmacy
pharmacy prescription
Dosage form
Dosage form
eye drops
Leo Pharmaceutical, Denmark
Fucitalmic
Release form
Futsitalmik. Eye drops in the form of a viscous suspension of white or almost white.
Packaging
In an aluminum tube 5 g drops. In the package 1 tube with a plastic tip.
cell. Pharmacological action of
Fusidic acid belongs to the group of fusidines, antimicrobial compounds whose mechanism of action is associated with impaired protein synthesis in the bacterial cell. By blocking the elongation of factor G, they prevent its binding to ribosomes and guanosine triphosphate, which interrupts the release of energy necessary for protein synthesis, and leads to the death of a bacterial cell.
Active against the microorganisms most commonly causing eye infections: Staphylococcus aureus.
Streptococcus pneumoniae.
Haemophilus influenzae.
Enterobacteriaciae and Pseudomonas spp. resistant to fusidic acid.
Pharmacokinetics
The dosage form of the drug (viscous eye drops) provides long-term contact with the conjunctiva and a sufficient concentration of fusidic acid in the lacrimal fluid, provided that it is used 2 times / day.
After 1, 3, 6 and 12 hours after a single application of Fucitalmic, the average concentration of fusidic acid in the tear fluid is 15.7 15.2 10.5 and 5.6 μg / ml, respectively. In the intraocular fluid, the concentration of fusidic acid is 0. 3 μg / ml (after single use) and 0.8 μg / ml (after repeated use), is achieved within 1 hour after application and is maintained for at least 12 hours, while fusidic acid is not detected in blood serum.
Indications
Treatment of bacterial infections of the eyes caused by microorganisms susceptible to the drug: Conjunctivitis.
blepharitis.
Keratitis.
Dacryocystitis.
Contraindications
Hypersensitivity to the components of the drug.
Preservative (benzalkonium chloride) is a potential allergen.
Use during pregnancy and lactation
There is no sufficient experience with the use of the drug during pregnancy and lactation (breastfeeding). It is possible to use as prescribed by the attending physician if the expected therapeutic effect exceeds the risk of developing possible side effects.
Composition of
1 g of eye drops contains:
Active ingredients
Fusidic acid micronized (in terms of anhydrous acid) 10 mg, equivalent to fusidic acid hemihydrate 10.17 mg.
Excipients
Benzalkonium chloride, disodium edetate, mannitol, carbomer 974P, sodium hydroxide, purified water.
Dosage and administration
1 drop in the conjunctival sac of the affected eye 2 times / day for 7 days.
In the absence of positive dynamics within 7 days of the use of the drug, therapy should be reviewed using other drugs.
Side effects
From the side of the organ of vision: in rare cases, allergic reactions (in the form of edema of the follicles of the transitional fold of the conjunctiva and urticaria) itching, burning, conjunctival hyperemia, soreness, lacrimation, swelling of the eyelids, aggravation of conjunctivitis.
Futsitalmik therapy should be discontinued in case of signs of hypersensitivity to the drug.
Drug Interaction
There are no drug interaction data.
Overdose
There is no overdose on the drug.
Storage conditions
At a temperature not exceeding 25 РC.
Shelf suitability
3 Year
Deystvuyuschee substances
Fuzydovaya acid
pharmacy
pharmacy prescription
Dosage form
Dosage form
eye drops
Leo Pharmaceutical, Denmark
Write Your Own Review